Yamashita Masahiro, Higo Hisao, Fujii Nobuharu, Matsumoto Chiaki, Makimoto Go, Ninomiya Kiichiro, Fujii Masanori, Rai Kammei, Ichihara Eiki, Ohashi Kadoaki, Hotta Katsuyuki, Tabata Masahiro, Maeda Yoshinobu, Miyahara Nobuaki
Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Department of Hematology and Oncology, Okayama University Hospital, Japan.
Respir Med Case Rep. 2024 Sep 2;51:102104. doi: 10.1016/j.rmcr.2024.102104. eCollection 2024.
A 56-year-old woman who received CD19 chimeric antigen receptor-T cell therapy for refractory diffuse large B-cell lymphoma developed severe coronavirus disease 2019 (COVID-19) and was treated with nirmatrelvir/ritonavir in April 2022. However, she experienced persistent fatigue and cough and fever in June. Computed tomography revealed bilateral ground-glass opacities (GGO), and the patient was treated with corticosteroids for organizing pneumonia after COVID-19. Partial improvement was observed, but new GGO appeared despite corticosteroid therapy. Genome analysis of severe acute respiratory syndrome coronavirus 2 detected Omicron variant BA.1.1.2, which was prevalent at the time of initial infection. The patient was diagnosed with protracted COVID-19 and was treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir, and tixagevimab/cilgavimab. These treatments appeared to contribute to the improvement of protracted COVID-19.
一名56岁女性因难治性弥漫性大B细胞淋巴瘤接受CD19嵌合抗原受体T细胞治疗，于2022年4月感染了严重的2019冠状病毒病（COVID-19），并接受了奈玛特韦/利托那韦治疗。然而，她在6月仍持续感到疲劳、咳嗽和发热。计算机断层扫描显示双侧磨玻璃影（GGO），该患者在COVID-19后因机化性肺炎接受了皮质类固醇治疗。观察到部分改善，但尽管进行了皮质类固醇治疗，仍出现了新的GGO。对严重急性呼吸综合征冠状病毒2的基因组分析检测到奥密克戎变异株BA.1.1.2，这是初次感染时流行的毒株。该患者被诊断为持续性COVID-19，并接受了瑞德西韦、莫努匹拉韦、奈玛特韦/利托那韦和替沙格韦单抗/西加韦单抗治疗。这些治疗似乎有助于改善持续性COVID-19。
